Evidence map›Paper›PMID 26273123›Full record

ArticleDisease markers2015

The Effect of PAI-1 4G/5G Polymorphism and Clinical Factors on Coronary Artery Occlusion in Myocardial Infarction.

Tajinder Kumar Parpugga, Vacis Tatarunas, Vilius Skipskis, Nora Kupstyte, Diana Zaliaduonyte-Peksiene, Vaiva Lesauskaite

Abstract read
In one paragraph

Article in Disease markers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tajinder Kumar ParpuggaInstitute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 17, LT-50009 Kaunas, Lithuania.
Vacis TatarunasInstitute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 17, LT-50009 Kaunas, Lithuania.
Vilius SkipskisInstitute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 17, LT-50009 Kaunas, Lithuania.
Nora KupstyteInstitute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 17, LT-50009 Kaunas, Lithuania ; Department of Cardiology, Lithuanian University of Health Sciences, Eiveniu 2, LT-50009 Kaunas, Lithuania.
Diana Zaliaduonyte-PeksieneDepartment of Cardiology, Lithuanian University of Health Sciences, Eiveniu 2, LT-50009 Kaunas, Lithuania.
Vaiva LesauskaiteInstitute of Cardiology, Lithuanian University of Health Sciences, Sukileliu 17, LT-50009 Kaunas, Lithuania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveData on the impact of PAI-1-675 4G/5G genotype for fibrinolysis during myocardial infarction are inconsistent. The aim of our study was to evaluate the association of clinical and genetic (PAI-1-675 4G/5G polymorphism) factors with coronary artery occlusion in patients with myocardial infarction. MATERIALS AND

methodsPAI-1-675 4G/5G detection was achieved by using Sanger sequencing in a sample of patients hospitalized for stent implantation due to myocardial infarction. We categorized the patients into two groups: patients with coronary artery occlusion and patients without coronary artery occlusion according to angiographic evaluation.

resultsWe identified n = 122 (32.4%) 4G/4G, n = 186 (49.5%) 4G/5G, and n = 68 (18.1%) 5G/5G PAI-1 genotype carriers. Univariate and multivariate analysis showed that only the 4G/5G genotype was associated with coronary artery occlusion (OR: 1.656 and 95% CI: 1.009-2.718, p = 0.046).

conclusionsOur results showed that carriers of PAI-1 4G/5G genotype with myocardial infarction have increased odds of coronary artery occlusion more than 1.6 times in comparison to the carriers of homozygous genotypes.

Indexed as

Polymorphism, Single NucleotideAdultAgedAged, 80 and overCase-Control StudiesCoronary Artery DiseaseFemaleHeterozygoteHomozygoteHumansMaleMiddle AgedMyocardial InfarctionPlasminogen Activator Inhibitor 1Plasminogen Activator Inhibitor 1SERPINE1 protein, human

Identifiers

PMID26273123
PMCPMC4529953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.